News | SPECT Imaging | September 23, 2015

Breakthrough SPECT Technology Wins Commercial Innovation of the Year at WMIC 2015

Show attendees award new imaging system with higher resolution, sensitivity than traditional SPECT

WMIS, WMIC 2015, MILabs, G-SPECT, Commerical Innovation of the Year, SPECT, PET, molecular imaging

G-SPECT photo courtesy of MILabs Inc.

September 23, 2015 — The World Molecular Imaging Society (WMIS) presented the first annual Commercial Innovation of the Year Award at the 2015 World Molecular Imaging Congress (WMIC) to Frederik Beekman, CEO/CSO, MILabs for his work developing G-SPECT.   

The award winner was chosen based on votes from WMIC attendees for the unique clinical single-photon emission computed tomography (SPECT) platform that allows for < 3mm resolution, low-dose studies and imaging of fast tracer dynamics. Beekman and his team began work on G-SPECT in 2006, with hopes to translate their proprietary microSPECT technologies into a clinical machine. Given the current field-of-view available for this system and its unique potential for fast dynamic imaging, first applications are expected in brain, bone and pediatric imaging. A large field-of-view option for G-SPECT is already under development.

SPECT and positron emission tomography (PET) are two of the most important molecular imaging modalities in use for diagnosis and therapy follow-up. Today, SPECT imaging is applied to millions of patients each year. Although SPECT is a very useful tool, current resolution of typically 7-10 mm can limit diagnostic precision. MILabs has shown that this can be changed: The new G-SPECT has high sensitivity and far superior resolution compared to current clinical SPECT systems and has fast dynamic imaging capabilities.

WMIS asked members of the industry to submit abstracts for this award and six semi-finalists were chosen to present their innovation at WMIC. Semi-finalists were given three minutes to present, then the audience was given the opportunity to vote on the innovation of their choice. The six semi-finalists were selected from 28 submissions following a scientific review by unbiased reviewers. 

Two other innovations recognized as finalists for the 2015 Commercial Innovation of the Year Award:

  • Jeff Harford of LI-COR was selected as first runner-up for his abstract titled, "Targeted Photodestruction of Tumors Using Bioconjugates of Near-Infrared IRDye 700DX."
  • The second runner-up was Christian Wiest of iThera for his abstract titled, "The world's first tomographic hybrid OPtoacoustic/UltraSound imaging technology."

For more information: www.milabs.com

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init